Imatinib Sandoz (Imatinib)

Imatinib binds to the ATP‑binding sites of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases, preventing their activation. This blocks downstream signaling pathways that normally promote cell proliferation and survival, leading to apoptosis of malignant cells while largely sparing normal tissues.

The dosage of Imatinib Sandoz is individualized and must be determined by a qualified prescriber based on the specific indication, disease stage, patient weight, renal and hepatic function, and other clinical factors. Patients should follow the dosing instructions provided by their healthcare professional.

Safety data for Imatinib in pregnancy and lactation are limited. Because the drug can cross the placenta and is excreted in breast milk, it is generally advised that women of child‑bearing potential discuss potential risks with their physician. Alternative therapies may be considered when possible.

To place an order, submit an enquiry on the Imatinib Sandoz product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team will then respond with pricing, availability, shipping details (including any temperature‑controlled requirements) and necessary import documentation.

Imatinib was the first BCR‑ABL tyrosine kinase inhibitor and remains a standard first‑line option for CML and GIST. Newer TKIs such as dasatinib or nilotinib may offer faster molecular responses or activity against certain resistant mutations, but they can have different safety profiles. Choice of therapy depends on disease characteristics, mutation status, comorbidities and physician judgment.

Imatinib Sandoz tablets should be stored at temperatures below 25 °C, in the original container, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposure to extreme heat or humidity to maintain potency.

Imatinib Sandoz is taken orally, usually with a glass of water. It can be taken with or without food, but patients should follow any specific instructions from their prescriber. Swallow the tablet whole; do not crush or chew unless directed by a healthcare professional.

Serious adverse events include severe neutropenia or leukopenia, hepatotoxicity, cardiac dysfunction (including reduced left‑ventricular ejection fraction), and rare but life‑threatening hemorrhage or gastrointestinal perforation. Patients should be monitored regularly for blood count changes, liver enzyme elevations, and cardiac symptoms, and report any unusual signs promptly.

Imatinib is contraindicated in patients with known hypersensitivity to imatinib or any of its excipients. Caution is advised for individuals with severe hepatic impairment, uncontrolled infections, or pre‑existing cardiac failure. Pregnant or breastfeeding women should only use the drug if the potential benefit outweighs the risk, after thorough consultation with a physician.